NCT05295875 is a Phase 2 clinical trial of ALT-801 in Obesity/Overweight, sponsored by Altimmune, Inc..

Who is sponsoring NCT05295875?

NCT05295875 is sponsored by Altimmune, Inc..

What drugs are being tested in NCT05295875?

Interventions in NCT05295875: ALT-801, Placebo.

What condition does NCT05295875 study?

NCT05295875 studies Obesity/Overweight.

Is NCT05295875 still recruiting?

NCT05295875 is currently completed. Last updated 29 November 2023.

Last reviewed 2023-11-29 · How we verify

NCT05295875

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of ALT-801 in the Treatment of Obesity

Completed Phase 2 Last updated 29 November 2023

What this trial tests

Phase 2 trial testing ALT-801 in Obesity/Overweight in 391 participants. Completed in 28 September 2023.

Timeline

31 March 2022

Primary endpoint
28 September 2023

28 September 2023

Quick facts

Lead sponsor	Altimmune, Inc.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	391
Start date	31 March 2022
Primary completion	28 September 2023
Estimated completion	28 September 2023
Sites	31 locations across United States

Drugs / interventions tested

ALT-801 — full drug profile →
Placebo

Conditions studied

Obesity/Overweight — all drugs for Obesity/Overweight →

Sponsor

Altimmune, Inc. — full company profile →

Who can join

Adults 18 to 75, any sex, with Obesity/Overweight. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the efficacy and safety of ALT-801 once-weekly versus placebo as an adjunct to a reduced-calorie diet and increased physical activity in patients with obesity/overweight.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of ALT-801

Trials testing the same drug.

NCT05292911 — Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD) · Phase 1 · completed
NCT05134662 — ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM) · Phase 1 · completed
NCT05006885 — ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD) · Phase 1 · completed
NCT04561245 — ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability · Phase 1 · completed
NCT01670994 — QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma · Phase 1, PHASE2 · terminated

Other recruiting trials for Obesity/Overweight

Currently open trials in the same condition.

NCT07144098 — Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Liver Insufficiency and Normal Liver Function · Phase 1 · recruiting
NCT07017179 — This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight · Phase 2 · recruiting
NCT07141030 — Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Renal Impairment and Normal Renal Function · Phase 1 · recruiting

Other Altimmune, Inc. trials

Trials by the same sponsor.

NCT07009860 — RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated · Phase 2 · recruiting
NCT05989711 — IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) · Phase 2 · completed
NCT05292911 — Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD) · Phase 1 · completed
NCT05134662 — ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM) · Phase 1 · completed
NCT05006885 — ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD) · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05295875 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Altimmune, Inc.
Last refreshed: 29 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05295875.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing